EMV Capital: AMR Bio targets FDA meeting to clear path for XF-73 Phase 3 trial

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev and AMR Bio chair Nigel Brooksby joined Proactive's Stephen Gunnion to discuss progress on XF-73, the antimicrobial drug candidate advancing towards Phase 3, and the milestones that could define the company's next stage of growth. Iliev said EMV Capital is supporting AMR Bio through its Venture Build programme, combining financial backing with hands-on value creation, and believes the next nine to twelve months could represent an important inflection point for the asset. Brooksby outlined preparations for a Type B meeting with the FDA to discuss the final Phase 3 programme, saying regulatory alignment would significantly de-risk development and increase pharma industry interest. He highlighted XF-73's advantages over the current standard of care, Mupirocin: "XF is the new gold standard, will deliver a 90% reduction in Staphylococcus aureus in just four doses over 24 hours. And we've clearly demonstrated zero resistance after over 55 passages. So it's not just an incremental improvement, it's a different weapon entirely." Iliev added that reaching Phase 3 readiness within two years of formation would validate EMV Capital's Venture Build model, with capital-light funding approaches already under consideration for the Phase 3 programme. For more interviews with leading companies and market experts, visit the Proactive YouTube channel. If you enjoyed this video, please give it a like, subscribe to the channel and enable notifications so you never miss future updates. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #EMVCapital #AMRBio #XF73 #AntimicrobialResistance #AMR #Biotech #Healthcare #DrugDevelopment #Phase3 #FDA #ClinicalTrials #InfectionPrevention #MedTech #LifeSciences #Investing #Proactive